Theriva Biologics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
/ 
Frequently asked questions
To buy Theriva Biologics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Theriva Biologics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Theriva Biologics Inc. is TOVX:xase. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Theriva Biologics Inc. has its primary listing on NYSE American. You can trade Theriva Biologics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Theriva Biologics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Theriva Biologics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Theriva Biologics Inc..